Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/32830
Title: A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice
Authors: Gentil, Fernanda
Bargieri, Daniel Y. [UNIFESP]
Leite, Juliana A.
Francoso, Katia S.
Patricio, Mariana B. M.
Espindola, Noeli M.
Vaz, Adelaide J.
Palatnik-de-Sousa, Clarisa B.
Rodrigues, Mauricio M. [UNIFESP]
Costa, Fabio Trindade Maranhão [UNIFESP]
Soares, Irene S.
Universidade de São Paulo (USP)
Universidade Federal de São Paulo (UNIFESP)
Universidade Estadual de Campinas (UNICAMP)
Universidade Federal do Rio de Janeiro (UFRJ)
Keywords: Malaria
Plasmodium vivax
Recombinant vaccine
Issue Date: 31-Aug-2010
Publisher: Elsevier B.V.
Citation: Vaccine. Oxford: Elsevier B.V., v. 28, n. 38, p. 6183-6190, 2010.
Abstract: The Apical Membrane Antigen 1 (AMA-1) is considered a promising candidate for development of a malaria vaccine against asexual stages of Plasmodium. We recently identified domain II (DII) of Plasmodium vivax AMA-1 (PvAMA-1) as a highly immunogenic region recognised by IgG antibodies present in many individuals during patent infection with P. vivax. the present study was designed to evaluate the immunogenic properties of a bacterial recombinant protein containing PvAMA-1 DII. To accomplish this, the recombinant protein was administered to mice in the presence of each of the following six adjuvants: Complete/Incomplete Freund's Adjuvant (CFA/IFA), aluminium hydroxide (Alum), Quil A, QS21 saponin, CpG-ODN 1826 and TiterMax. We found that recombinant DII was highly immunogenic in BALB/c mice when administered in the presence of any of the tested adjuvants. Importantly, we show that DII-specific antibodies recognised the native AMA-1 protein expressed on the surface of P. vivax merozoites isolated from the blood of infected patients. These results demonstrate that a recombinant protein containing PvAMA-1 DII is immunogenic when administered in different adjuvant formulations, and indicate that this region of the AMA-1 protein should continue to be evaluated as part of a subunit vaccine against vivax malaria. (C) 2010 Elsevier B.V. All rights reserved.
URI: http://repositorio.unifesp.br/handle/11600/32830
ISSN: 0264-410X
Other Identifiers: http://dx.doi.org/10.1016/j.vaccine.2010.07.017
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.